Breaking News

Ferguson Shooting Grand Jury Reaches Decision, Law Firm Says
Tweet TWEET

Pre-Market Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Health Solutions Inc., and Allergan Inc.

  Pre-Market Review: Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Health
                      Solutions Inc., and Allergan Inc.

PR Newswire

LONDON, September 17, 2013

LONDON, September 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Monday, September 16, 2013, the U.S. equity market ended on a mixed note.
The S&P 500 and the Dow Jones Industrial Average gained 0.57% and 0.77%
respectively, while the NASDAQ Composite fell by 0.12%. Shares in healthcare-
drug makers made advances, even as the broader market fluctuated between gains
and losses. The major movers in the industry included Bristol-Myers Squibb
Company (NYSE: BMY), Eli Lilly & Company (NYSE: LLY), Endo Health Solutions
Inc. (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). AAAResearchReports.com
initiated preliminary technical research on BMY, LLY, ENDP, and AGN. These
free reports are accessible by signing today at:

http://www.aaaresearchreports.com/register/ 

Shares in Bristol-Myers Squibb Co. surged on Monday, extending the gains from
the previous trading session. The company's shares finished the day 3.63%
higher at $45.14 after trading between $44.37 and $45.42. A total of 10.21
million shares were traded, which is above the daily average volume of 7.36
million. The company's shares have gained 4.35% in the previous three trading
sessions and 8.30% in the last one month, outperforming the S&P 500 which has
advanced 0.50% and 2.52% during the respective periods. Further, Bristol-Myers
Squibb Co.'s stock is trading above its 50-day and 200-day moving averages of
$43.33 and $40.15, respectively. The free technical analysis on BMY is
available by signing up at:

http://www.AAAResearchReports.com/BMY091713.pdf

On Monday, Eli Lilly & Co.'s stock advanced to close at $53.64, up 0.69% from
the previous day's closing price of $53.27. The company's shares oscillated
between $53.43 and $53.84 during the trading session. A total of 2.67 million
shares were traded, which is below the daily average volume of 5.07 million.
The company's shares are up 1.59% in the previous three trading sessions and
3.05% in the last three months, compared to a gain of 0.50% and 4.36% in the
S&P 500 during the respective periods. Additionally, Eli Lilly & Co.'s stock
is trading above its 50-day and 200-day moving averages of $52.41 and $53.11,
respectively. Register now to download free research on LLY at:

http://www.AAAResearchReports.com/LLY091713.pdf

Shares in Endo Health Solutions Inc. rose marginally on Monday, even as the
broader market ended on a mixed note. The company's shares fluctuated between
$43.71 and $44.40 before ending the day 0.09% higher at $43.74. A total of
1.40 million shares were traded, which is below the daily average volume of
1.68 million. The company's shares have surged 18.83% in the last one month
and 12.79% in the previous three months, outperforming the S&P 500 during both
the periods. Moreover, Endo Health Solutions Inc.'s stock is trading near its
52-week high of $44.73 as well as above its 50-day and 200-day moving averages
of $39.33 and $33.79, respectively. A free report on ENDP can be accessed by
registering at:

http://www.AAAResearchReports.com/ENDP091713.pdf

Allergan Inc.'s stock rose 0.57% on Monday, extending the gains from the
previous trading session. The company's shares closed the day at $89.28, after
oscillating between $88.89 and $89.85. A total of 0.99 million shares were
traded, which is below the daily average volume of 2.48 million. The company's
shares have advanced 1.74% in the previous three trading sessions, compared to
a gain of 0.50% in the S&P 500 during the same period. Despite Monday's gain,
Allergan Inc.'s stock is trading below its 50-day and 200-day moving averages
of $89.87 and $99.56, respectively. Register with AAA Research Reports and
download research on AGN for free at:

http://www.AAAResearchReports.com/AGN091713.pdf

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: +1(646)396-9126 ; Peter F. Jones; info@aaaresearchreports.com
 
Press spacebar to pause and continue. Press esc to stop.